STL Partnership partnered with state and local leaders in supporting Pfizer's decision to stay and grow in St. Louis County.
Pfizer Inc. (NYSE:PFE) announced the opening of a new 295,000 square-foot research and development facility in Chesterfield, Missouri. The site will house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners to advance Pfizer’s biologics, vaccines, and gene therapy portfolio. The $236 million investment builds on Pfizer’s leading worldwide research and development network.
“The Chesterfield site is an important expansion of our R&D capabilities and is designed to support the development of potential new medicines and vaccines” said Mikael Dolsten, M.D., Ph.D., Pfizer Chief Scientific Officer and President, Worldwide Research, Development, and Medical. “Together, we will attempt to accelerate scientific breakthroughs and realize our commitment to patients to transform their lives.”
Pfizer’s new site, with its open and collaborative design, will develop manufacturing processes, dosage forms, and analytics to deliver clinical and commercial supplies with industry-leading speed and quality in a variety of therapeutic areas including oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars. It will also enable the manufacturing of plasmids for gene therapy clinical supplies as well as work to develop innovative gene therapy manufacturing technologies and solutions.
“We are pleased that Pfizer has chosen to invest in Missouri and grow its presence here within the life sciences community in the Midwest,” said Mike Parson, Governor of Missouri. “This is an important facility that will benefit the Chesterfield community and help improve the lives of many Missourians as well as patients around the world.”
The facility brings together some 450 existing Pfizer colleagues and provides more than 80 new positions in Chesterfield. It offers new state-of-the-art features, including flexible laboratory layouts and open floor plans to encourage collaboration across functions and colleagues — including engineers, biologists, biochemists, analytical chemists and pharmacy specialists. The expansion was supported by the St. Louis Economic Development Partnership.
“Pfizer’s choice of St. Louis County for this new facility is a testament to our skilled workforce as well as our growing international reputation as a center for research in the biopharma, plant science and information technology fields,” St. Louis County Executive Sam Page said. “The company’s investment in this expansion is one of the largest in the history of St. Louis County. But beyond the economic benefit for our region, the focus of Pfizer’s research and development work here will save lives and relieve suffering around the world.”
The opening of the Chesterfield facility comes days after the opening of Pfizer’s new 175,000 square-foot manufacturing facility in Andover, Mass. Pfizer’s Andover site houses clinical and commercial manufacturing and product development functions, with colleagues dedicated to the development and production of high-quality complex biologics and vaccines.
The grand opening of the Chesterfield facility was to be celebrated with a ribbon-cutting ceremony in front of the new 875 Chesterfield Parkway W., Chesterfield, MO. facility.
For additional details, please contact Pfizer Global Media Relations: Samantha Reardon at 212-733-1461 or [email protected].
Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best‐known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of May 30, 2019. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer’s new research and development facility in Chesterfield, Missouri, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the new facility; other business effects, including the effects of industry, market, economic, political or regulatory conditions; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
# # # # #